Evaluation of the BioFire FilmArray Pneumonia Panel Plus to the Conventional Diagnostic Methods in Determining the Microbiological Etiology of Hospital-Acquired Pneumonia

• Published in: Biology (Basel, Switzerland) Switzerland), 2022-02, Vol.11 (3), p.377
• Main Authors: Kamel, Noha A, Alshahrani, Mohammad Y, Aboshanab, Khaled M, El Borhamy, Mervat I
• Format: Article
• Language: English
• Subjects: Antibiotic resistance; antibiotic sensitivity; Antibiotic sensitivity testing; Antibiotics; Bacteria; Bronchus; Chlamydia; Coronaviruses; COVID-19; Diagnosis; Etiology; FilmArray; Genetic markers; Gram-negative bacteria; Gram-positive bacteria; hospital-acquired pneumonia; Influenza; Intensive care; Laboratories; Manufacturers; Methods; Morbidity; Mortality; Multidrug resistance; multiplexed BioFire Pneumonia Panel plus; Nosocomial infections; Pathogens; Phenotypes; Pneumonia; Process controls; Public health; Respiratory diseases; Respiratory syncytial virus; Respiratory tract diseases; Sensitivity analysis; Staphylococcus infections; Streptococcus infections; Ventilators; Viruses
• ISSN: 2079-7737; 2079-7737
• DOI: 10.3390/biology11030377

Hospital-acquired pneumonia (HAP) is a substantial public health issue that is associated with high mortality rates and is complicated by an arsenal of microbial etiologies, expressing multidrug-resistant phenotypes, rendering relatively limited therapeutic options. BioFire FilmArray Pneumonia Panel plus (BFPP) is a simple multiplexed PCR system that integrates sample preparation, nucleic acid extraction, amplification, and analysis of microbial etiology, with a turnaround time of about one hour. In comparison to standard culture methods, BFPP is simpler, easier to perform, and can simultaneously detect the most common pathogens involved in lower respiratory tract infections (34 targets). Accordingly, we evaluated the diagnostic performance of the multiplexed BFPP for the rapid detection of 27 clinically relevant respiratory pathogens and 7 genetic markers among 50 HAP cases admitted to the intensive care unit (ICU), who submitted mini-bronchoalveolar (mBAL) specimens. In comparison to standard culture methods, BFPP showed an overall sensitivity of 100% [95% CI; 90-100] and overall specificity of 90% [95% CI; 87.4-92.5] among all the tested bacterial targets. BFPP identified 11 viral targets (22%) among the tested specimens. The BFPP semi-quantitative analysis showed a concordance rate of 47.4% among positive culture specimens. For the investigation of the antibiotic resistance genes, BFPP showed a positive percent agreement (PPA), a negative percent agreement (NPA), and an overall percent agreement (OPA), reaching 97% [95% CI; 90-100], 95% [95% CI; 91.5-97], and 95% [95% CI; 93-97], respectively, with standard antibiotic sensitivity testing. In conclusion, BFPP has the potential to enhance the rapid microbiological diagnosis of HAP cases, and could aid in tailoring appropriate antibiotic therapies.